Clinical trial reportCancer chemotherapy and pharmacologyPublished
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer
Regional connection
Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source
- Counties
- Montgomery County, Philadelphia County
Publication record
- Type
- Clinical trial report
- Venue
- Cancer chemotherapy and pharmacology
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Prostate-Specific Antigen; Glutamate Carboxypeptidase II; Antibodies, Bispecific; Antigens, Surface; Dose-Response Relationship, Drug; Aged; Aged, 80 and over; Middle Aged; Male; Prostatic Neoplasms, Castration-Resistant; CD3 Complex
- PubMed ID
- 41493473
- PubMed Central ID
- PMC12774958
- Open access
- Yes, open
- Added to directory
- Source checked